Where the stock stands
The evidence pack for AGARWALEYE carries no price block and no technical readings, so this page cannot say where the shares trade or how they have moved recently. What it does carry is a valuation snapshot dated 7 October 2026. On that snapshot the stock sits at a price-to-earnings multiple of 103.92 on earnings per share of ₹4.65, and a price-to-book ratio of 7.56. Market capitalisation is recorded at ₹15320 crore, and the dividend yield field reads zero. The sector field is listed as unknown, so the data offers no peer group against which to judge whether that multiple is high or low for its industry.
What the smart-money flow shows
All eight institutional deal rows in the pack fall on a single day, 12 August 2026, and the shape of that day is clear from the counterparties. Two sellers dominate: Hyperion Investments Pte. Ltd. sold shares worth ₹1210.49 crore and Claymore Investments (Mauritius) Pte. Ltd. sold ₹797.45 crore. Both are tagged with the category "Other", and the pack gives no further detail on who they are or why they sold, so this page does not characterise them beyond the names.
On the other side, the buyers were a mix of domestic and overseas funds. ICICI Prudential Mutual Fund bought ₹311.21 crore, the largest single purchase. Polar Capital Funds PLC, through its Healthcare Opportunities Fund, bought ₹181.68 crore. Invesco Mutual Fund bought ₹179.93 crore; note that the pack labels this row "FII" even though the name reads as a mutual fund, and the data does not resolve which is correct. Allianz Global Investors, acting for its Allianz EEE Fonds, bought ₹88.78 crore. Marwadi Chandarana Intermediaries Brokers appears on both sides the same day, buying ₹98.47 crore and selling ₹33.25 crore. That is two-sided broker flow rather than a clean position, and it is best read as intermediary activity, not accumulation.
Taken together, the rows describe a large block of stock leaving two holders and being absorbed by a spread of funds on one day. Beyond that day the pack is silent: it holds no futures and options positioning, no multi-day institutional buying or selling streak, and no insider filings.
The technical picture
The pack contains no technical data at all, with no moving averages, momentum readings, volume figures or support levels. This page therefore makes no statement about the chart.
Catalysts and what to watch
The catalyst list is dominated by one corporate action. According to exchange filings on NSE, Dr. Agarwal's Health Care Limited told the exchange it has received sanction from the NCLT Chennai Bench for the scheme of amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited. The same filing appears three times, dated 5, 6 and 7 October, so it is one event rather than three. The feed tags it as an acquisition with a bullish bias, but the filing itself describes a merger of the two named entities, not a purchase of an outside business. Earlier filings dated 20, 21 and 22 July enclosed a newspaper notice of the hearing on that same petition, which places the October sanction as the next step in a process already under way.
Among news headlines, Kalkine India reported a trading-window closure for Q2 FY27, and a headline from Sahi said the company had scheduled a meeting with analysts and investors for September 16, a date that has since passed. The pack records no outcome from either.
What the data establishes is a single heavy day of institutional deals in August, with two large sellers and several funds buying, and a court sanction for the amalgamation in October. It does not establish the current share price, any trend in the stock, or how the merger will change the company's numbers.